相关实验视频

Updated: May 24, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

一种新型的lncRNAFLJ通过AR介导的自性促进前列腺癌中的割抗性

Yingying Wu^1,2, Shaojie Cheng³, Ting Zhang²

¹Department of Clinical Laboratory, Chongqing University Fuling Hospital, Chongqing, China.

Journal of translational medicine

|March 3, 2025

概括

长非编码RNAFLJ通过激活雄激素受体 (AR) 信号通路来促进割抵抗性前列腺癌 (CRPC). 针对FLJ-AR轴为CRPC患者提供了一个新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

抗割前列腺癌 (CRPC) 是前列腺癌患者死亡的主要原因.
长非编码RNAs (lncRNAs) 越来越多地被认为是它们在癌症发展中的作用.
已经确定了一些涉及CRPC进展的lncRNA.

研究的目的:

为了识别和描述参与CRPC进展的新型lncRNAs.
阐明CRPC中发现的lncRNA,FLJ的调节机制.
评估针对FLJ-AR信号轴的治疗潜力.

主要方法:

RNA测序和定量聚合酶链反应 (qRT-PCR) 用于lncRNA的识别和验证.
在体外和体外功能测定 (例如,敲击研究) 来评估FLJ在CRPC细胞中的作用.
使用诸如双露西法酶记者测定和染色体免疫沉 (ChIP) 等技术进行分子机制研究.

主要成果:

FLJ在CRPC中表达很高,与晚期疾病阶段和更高的格里森得分相关.
FLJ表达受到雄激素受体 (AR) 的积极调节,该受体直接与FLJ促进体结合.
FLJ敲击抑制了CRPC细胞增殖,增强了对割和恩扎胺 (ENZA) 的敏感性,抑制了体内瘤生长,并改善了ENZA的治疗疗效.

结论:

lncRNA FLJ通过一种涉及持续AR激活的新机制促进CRPC进展.
FLJ通过抑制AR核进口和促进细胞质降解来绕过雄激素依赖,从而激活AR信号.
针对FLJ-AR信号轴为CRPC治疗提供了一个有前途的治疗策略.

关键词:

雄激素受体 (AR) 是一种自自是一种自的过程.对割的抗性有所抵抗.化抵抗性前列腺癌 (CRPC) 是一种癌症.在cRNA FLJ中.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...